Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. [electronic resource]
Producer: 20150114Description: 220-2 p. digitalISSN:- 1365-2133
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Drug Administration Schedule
- Humans
- Indoles -- administration & dosage
- Male
- Melanoma -- drug therapy
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Skin Neoplasms -- drug therapy
- Sulfonamides -- administration & dosage
- Vemurafenib
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.